| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2018-07-10 |
复牌提示：
2018-07-09 13:34:42 停牌，复牌日期 2018-07-09 13:39:42
|
| 2018-04-02 |
详情>>
股本变动：
变动后总股本896.18万股
|
| 2018-04-02 |
详情>>
业绩披露：
2017年年报每股收益-8.56美元,归母净利润-3279.14万美元,同比去年增长-85.68%
|
| 2017-11-22 |
股东大会：
将于2017-12-01召开股东大会
会议内容 ▼▲
- 1.To approve the potential issuance of up to an aggregate of 9,666,667 shares of common stock, in excess of 19.99% of the number of shares of common stock that were issued and outstanding on October 17, 2017, upon the conversion of 58,000 shares of the Company’s newly authorized Series L Convertible Preferred Stock, which were issued to certain holders of the Company’s Preferred Stock pursuant to Exchange Agreements dated October 18, 2017;
2.To ratify the issuance of up to an aggregate of 2,900,000 restricted shares of common stock to certain investors in the Company’s May 2017 public offering, in excess of 19.99% of the number of shares of common stock that were issued and outstanding on May 3, 2017, including 1,968,664 shares of common stock underlying the Company’s Series I Convertible Preferred Stock;
3.To authorize an amendment to the Company’s Fifth Amended and Restated 2014 Employee, Director and Consultant Equity Incentive Plan to increase the number of shares available for issuance thereunder to 10,128,406 shares from 6,128,406 shares, representing an increase of 4,000,000 shares, to increase the number of shares available for issuance under the “evergreen” provision and to increase the number of shares issuable to any one participant in any fiscal year to 3,600,000 shares, representing an increase of 2,600,000 shares.
|
| 2017-11-07 |
详情>>
业绩披露：
2017年三季报(累计)每股收益-2.68美元,归母净利润-2278.43万美元,同比去年增长-81.54%
|
| 2017-10-03 |
股东大会：
将于2017-10-06召开股东大会
会议内容 ▼▲
- 1)To grant the Board of Directors the authority, in its sole direction, in determining a higher stock price is required to continue to meet the continued listing qualifications for The Nasdaq Capital Market, to approve an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our issued and outstanding common stock by a ratio of not less than one-for-two and not more than one-for-twenty at any time prior to September 28, 2018, with the exact ratio to be set at a whole number within this range as determined by the Board of Directors;
2)To approve the potential issuance of up to an aggregate of 3,400,000 shares of common stock, in excess of 19.99% of the number of shares of common stock that were issued and outstanding on August 11, 2017, consisting of (i) 2,386,360 shares of common stock issuable upon conversion of Series J Preferred Stock, issued to investors in a financing consummated in August 2017 and (ii) 1,013,640 shares of common stock available for issuance under designated but unissued shares of Series J Preferred Stock;
3)If Proposal 2 is approved, to approve the potential issuance of up to 6,500,000 shares of common stock upon conversion of Series K Preferred Stock issuable in connection with a financing consummated in August 2017, in excess of 19.99% of the number of shares of common stock that were issued and outstanding on August 11, 2017;
4)To authorize the issuance of securities in one or more non-public offerings where the maximum discount at which securities will be offered will be equivalent to a discount of 30% below the market price of the common stock, as required by and in accordance with Nasdaq Marketplace Rule 5635(d);
5)To authorize the issuance of securities in one or more non-public offerings where the maximum discount at which securities will be offered will be equivalent to a discount of 20% below the market price of the common stock, as required by and in accordance with Nasdaq Marketplace Rule 5635(d);
6)To approve the Fifth Amended and Restated MabVax Therapeutics Holdings, Inc. 2014 Employee, Director and Consultant Equity Incentive Plan, including the reservation of 6,128,406 shares of common stock for issuance;
7)To transact other business that may properly come before the meeting and any postponement(s) or adjournment(s) thereof.
|
| 2017-09-06 |
股东大会：
将于2017-09-28召开股东大会
会议内容 ▼▲
- 1. To grant the Board of Directors the authority, in its sole direction, in determining a higher stock price is required to continue to meet the continued listing qualifications for The Nasdaq Capital Market, to approve an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our issued and outstanding common stock by a ratio of not less than one-for-two and not more than one-for-twenty at any time prior to September 28, 2018, with the exact ratio to be set at a whole number within this range as determined by the Board of Directors;
2. To approve the potential issuance of up to an aggregate of 3,400,000 shares of common stock, in excess of 19.99% of the number of shares of common stock that were issued and outstanding on August 11, 2017, consisting of (i) 2,386,360 shares of common stock issuable upon conversion of Series J Preferred Stock, issued to investors in a financing consummated in August 2017 and (ii) 1,013,640 shares of common stock available for issuance under designated but unissued shares of Series J Preferred Stock;
3. If Proposal 2 is approved, to approve the potential issuance of up to 6,500,000 shares of common stock upon conversion of Series K Preferred Stock issuable in connection with a financing consummated in August 2017, in excess of 19.99% of the number of shares of common stock that were issued and outstanding on August 11, 2017;
4. To authorize the issuance of securities in one or more non-public offerings where the maximum discount at which securities will be offered will be equivalent to a discount of 30% below the market price of the common stock, as required by and in accordance with Nasdaq Marketplace Rule 5635(d);
5. To authorize the issuance of securities in one or more non-public offerings where the maximum discount at which securities will be offered will be equivalent to a discount of 20% below the market price of the common stock, as required by and in accordance with Nasdaq Marketplace Rule 5635(d);
6. To approve the Fifth Amended and Restated MabVax Therapeutics Holdings, Inc. 2014 Employee, Director and Consultant Equity Incentive Plan, including the reservation of 6,128,406 shares of common stock for issuance;
7. To transact other business that may properly come before the meeting and any postponement(s) or adjournment(s) thereof.
|
| 2017-08-14 |
详情>>
业绩披露：
2017年中报每股收益-2.37美元,归母净利润-1658.41万美元,同比去年增长-102.42%
|
| 2017-05-22 |
详情>>
业绩披露：
2017年一季报每股收益-0.85美元,归母净利润-535.49万美元,同比去年增长-21.57%
|
| 2017-05-03 |
股东大会：
将于2017-06-12召开股东大会
会议内容 ▼▲
- 1)To elect two Class II directors to serve until the 2020 Annual Meeting of Stockholders;
2)To grant the Board of Directors the authority to amend our Third Amended and Restated 2014 Employee, Director and Consultant Equity Incentive Plan to increase the number of shares available for issuance thereunder to 4,128,406 from 2,159,352;
3)To ratify the appointment of CohnReznick LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2017;
4)To authorize the adjournment of the Annual Meeting if necessary or appropriate, including to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting or adjournment or postponement thereof to approve any of the foregoing proposals;
5)To transact other business that may properly come before the meeting and any postponement(s) or adjournment(s) thereof.
|
| 2017-03-01 |
详情>>
业绩披露：
2016年年报每股收益-3.64美元,归母净利润-1766.05万美元,同比去年增长51.01%
|
| 2016-11-07 |
详情>>
业绩披露：
2016年三季报(累计)每股收益-2.87美元,归母净利润-1255.05万美元,同比去年增长60.86%
|
| 2016-08-17 |
详情>>
内部人交易：
Cohen Kenneth M等共交易4笔
|
| 2016-08-16 |
详情>>
业绩披露：
2016年中报每股收益-2.03美元,归母净利润-819.27万美元,同比去年增长69.42%
|
| 2016-08-16 |
详情>>
业绩披露：
2015年年报每股收益-13.44美元,归母净利润-3605.15万美元,同比去年增长-240.82%
|
| 2016-08-03 |
详情>>
业绩披露：
2016年一季报每股收益-0.15美元,归母净利润-440.48万美元,同比去年增长78.40%
|